Abstract Details

Title Are the choices of Therapeutic options for the Management of Myasthenia Gravis Crisis with acute respiratory failure-Influenced by the patient’s Age. A New York State Planning and Research Cooperation System Database Analysis (1998-2014)

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-030

Objective To investigate the age group difference for use of Intravenous Immunoglobulin (IVIG), Plasmapheresis (PE) and steroid in the treatment of MG crisis with ARF.

Background Previous studies reported that Myasthenia Gravis (MG) crisis complicated by acute respiratory failure (ARF) is more likely to be treated with plasmapheresis (PE).

Design/Methods We used New York Statewide Planning and Research Cooperation System database for the 1998-2014 period. Data was analyzed using IBM SPSS software.

Results A total of 496 patient encounters with MG crisis with ARF who received treatment were identified (mean age 63.3 years ± 18.1, 47.6% of whom were male) of which 20.2% were treated with IVIG, 30.66% with PE and 4.2% with steroids. Of these 66 (13.3%) patients were in the age group 20-49 years, 125 (25.2%) in age group 50-79 years , and 54 (10.9%) over the age of 80 years. 80 years and older patients were more likely to develop ARF (23.7%) than patients aged 50-79 years (13.5%) and patients aged 20-49 years (9.8%) (p-value < 0.05). 46.3% of 80 years and older patients were treated with IVIG compared to 30.3% patients aged 20-49 years and 32.8% patients aged 50-79 years p=0.41. 50% of 80 years and older patients were treated with PE compared to 59.1%% patients aged 20-49 years and 60.8%% patients aged 50-79 years p=0.77).

Conclusions Elderly patients are more likely to develop acute respiratory failure with MG crisis as compared to younger patients. No significant difference in the use of IVIG vs PE for the treatment of MG crisis between different age groups suggesting that age does not influence the choice of therapeutic options.

Authors/Disclosures
Shuja Sheikh, MD (Riverside Medical Center) PRESENTER	No disclosure on file
Kevin Nolasco	Kevin Nolasco has nothing to disclose.
Taha Nisar, MD (Rutgers New Jersey Medical School)	Dr. Nisar has nothing to disclose.
Abu Nasar	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��